Table 1.
APL relapse cases experienced in our institution between 1991 and 2015
| Sex/Age (years) | Cytogenesis | WBC (x 109/L) | Risk group (Sanz score) | CD56 | DS | CNS prohylaxis | PML‐RARA isoform | CNS bleeding | Time to 1st hematological relapse | Time to CNS invavsion/relapse | 1st induction therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M/68 | 46,XY,t(15;17)(q22;q21) | 3.4 | Intermediate | N | No | No | bcr3 | No | 16 M | 16 M | ATRA+CT |
| M/50 | 48,XY,+1,+8,del(11)(p 15)add(11) (q13),t(15;17)(q22;q21) | 1.2 | Low | N | No | No | NT | No | 14 M | – | ATRA |
| F/22 | 46,XX,t(15;17)(q22;q21) | 1.1 | Low | NT | No | No | NT | No | 9 M | – | CT |
| M/63 | 46,XY,t(15;17)(q22;q21) | 0.5 | Low | P | No | No | bcr3 | No | 10 M | – | ATRA |
| F/49 | 46XX,t(15;17)(q22;q21) | 15.2 | High | NT | No | No | bcr3 | No | 14 M | – | ATRA+CT |
| F/57 | 46,XX,t(15;17)(q22;q21) | 0.8 | Low | N | Yes | No | bcr3 | No | 13 M | 90 M (54 M after allo‐SCT) | ATRA+CT |
| M/70 | 46,XY,t(15;17)(q22;q12) | 16.6 | High | P | No | Yes (TIT) | NT | Yes | 30 M | 30 M | ATRA+CT |
M in sex, male; F in sex, female; WBC, white blood cell count; CNS, central nervous system; APL, acute promyelocytic leukemia; DS, differentiation syndrome; TIT, triple intrathecal therapy; BM, bone marrow; CR, complete remission; ATRA, all‐trans retinoic acid; CT, chemotherapy; allo‐SCT, allogeneic stem cell transplantation; NT, not tested; M in time, month.